Catalyst Calendar

Thu, Aug 6, 2026

1 updates

4:01 PM

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results anticipated in early Q1 2027 TX45 APEX Phase 2 clinical trial Independent Data Monitoring Committee

Enrollment • Phase 2Enrollment completion Tue, Jun 30, 2026tectonictx.com

Wed, Jun 10, 2026

1 updates

TECX

4:01 PM

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched

Enrollment • Phase 2Enrollment milestone Wed, Jun 10, 2026tectonictx.com